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The microenvironment within tumors is composed of a heterogeneous mixture of cells with
varying levels of nutrients and oxygen. Differences in oxygen content result in survival or
compensatory mechanisms within tumors that may favor a more malignant or lethal phe-
notype. Cells that are rapidly proliferating are richly nourished and preferentially located
close to blood vessels. Chemotherapy can target and kill cells that are adjacent to the vas-
culature, while cells that reside farther away are often not exposed to adequate amounts
of drug and may survive and repopulate following treatment. The characteristics of the
tumor microenvironment can be manipulated in order to design more effective therapies.
In this review, we describe important features of the tumor microenvironment and discuss
strategies whereby drug distribution and activity may be improved.
Keywords: drug distribution, pharmacodynamic markers, tumor microenvironment, drug penetration, hypoxia-
activated pro-drugs, solid tumor
INTRODUCTION
SOLID TUMORS AND DRUG RESISTANCE
The tumor microenvironment within solid tumors
Solid tumors contain a heterogeneous mixture of tumor cells and
non-malignant cells within an extracellular matrix (ECM) sup-
ported by an irregular vascular network. Tumor blood vessels are
often farther apart than in normal tissues, and have variable blood
flow, leading to poor delivery of nutrients and impaired clearance
of metabolic breakdown products from the tumor (Minchin-
ton and Tannock, 2006; Tredan et al., 2007). Many solid tumors
develop regions of hypoxia, which may lead to up-regulation
of genes that predispose to a more malignant phenotype (Wil-
son and Hay, 2011). Blood vessels are also the route by which
anticancer drugs are delivered to the tumor, and our laboratory
and others have shown that the limited blood supply may put
tumors at a disadvantage in terms of drug delivery as compared
to better-vascularized normal tissues (Hirst and Denekamp, 1979;
Minchinton and Tannock, 2006; Tredan et al., 2007). Also, poor
nutrition of tumor cells may lead to low rates of cell proliferation
in some tumor regions (Hirst and Denekamp, 1979; Ljungkvist
et al., 2002), and cells in such regions are likely to be resistant to
cycle-active drugs as shown in Figure 1A.
Tumor acidity
The poor vascular organization and lack of lymphatic drainage of
solid tumors contributes to a build up in metabolic byproducts
such as lactic and carbonic acids leading to a reduced extracel-
lular pH. The production of lactate arises from glycolysis – a
favored route of energy production in tumors. Glycolysis typically
takes place under hypoxic conditions, when oxidative phospho-
rylation is not possible, but in tumors glycolysis also takes place
in oxygenated regions (Song et al., 2006). Tumor acidity influ-
ences drug uptake into tumor cells. When the extracellular tumor
environment is acidic, chemotherapeutic drugs that are basic (such
as doxorubicin, mitoxantrone, vincristine, and vinblastine) are
protonated; this decreases cellular uptake since charged drugs pass
through the cellular membrane less efficiently than those that are
uncharged (Manallack, 2008). In contrast, drugs that are acidic
(such as chlorambucil and cyclophosphamide) will tend to con-
centrate within cells. Even if basic drugs pass through the cellular
membrane, sequestration within acidic organelles such as endo-
somes may occur, leaving less drug to attack tumor DNA and
produce antitumor effects (Mayer et al., 1986).
Tumor hypoxia
Hypoxia is a hallmark of many different tumor types. The con-
voluted vasculature of tumors can result in insufficient oxygen
supply through blood vessels as seen in Figure 1A. This type of
hypoxia is known as chronic or diffusion limited hypoxia. Acute
hypoxia may also occur in solid tumors due to intermittent blood
flow.
Cells that reside far away from functional blood vessels may
become hypoxic due to the limited diffusion of oxygen: the dis-
tance from blood vessels to hypoxic regions will depend on the
rate of oxygen consumption by the tumor cells, but typically
cells residing at a distance greater than 70µm from functional
blood vessels receive inadequate amounts of oxygen (Vaupel and
Harrison, 2004). Hypoxic cells can be viable, but usually pro-
liferate slowly, presumably due to their reduced production of
ATP; however recent work from our laboratory has shown that
as chemotherapy induces the death of cells close to blood vessels,
hypoxic cells may reoxygenate and proliferate, presumably because
of a better supply of nutrients and oxygen.
Hypoxia in tumors is associated with a poor clinical outcome
as compared to patients with tumors lacking hypoxia (Hockel
et al., 1996; Fyles et al., 2002; Nordsmark et al., 2005; Jubb et al.,
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FIGURE 1 | (A) Strategies to overcome limited drug distribution in solid
tumors. Solid tumors are featured by irregular and poorly organized
vasculature. This makes blood-borne oxygen and nutrients difficult to reach
tumors cells distant from vessels and eventually leads to formation of regions
with low oxygen (hypoxia) and nutrient concentrations. In these areas, tumor
cells are usually highly resistant to chemotherapy and radiation therapy. Drug
distribution in solid tumors is influenced by many factors, such as
physicochemical properties of drugs, consumption of drugs by cells proximal
to blood vessels, and the volume and organization of the extracellular matrix
(ECM). Strategies to enhance drug distribution in tumors (indicated by yellow
background and dashed lines) include increase of tumor blood flow, decrease
of high interstitial fluid pressure (IFP), and modification of ECM. Combination
treatment using “conventional” therapeutics together with drugs (e.g.,
hypoxia-activated pro-drugs and agents targeting autophagy) that are able to
specifically target cells distant from vasculature also have potential to improve
therapeutic efficacy. (B) Schematic representation of multilayered cell
cultures (MCCs) to quantify drug penetration. A drug is first added into the
small compartment above the MCC. After its passage from the semi-liquid
media through the MCC, drug is sampled from the receiving compartment
below the MCC and measured.
2010). The presence of hypoxia leads to up-regulation of genes
that promote a more malignant phenotype and favor cell sur-
vival. The transcription factor hypoxia inducible factor I (HIF-1)
is induced, and causes the synthesis of angiogenesis-relevant pro-
teins, suppression of apoptosis, and enhanced receptor tyrosine
kinase signaling (Mizukami et al., 2007). These in turn favor
epithelial to mesenchymal transition (EMT) – a process that is
associated with tumor invasiveness and metastasis (Wilson and
Hay, 2011). HIF-1 also induces the expression of carbonic anhy-
drase 9 (CA9) which favors the hydration of CO2 leading to the
production of carbonic acid – further contributing to a decrease
in extracellular pH (Potter and Harris, 2004).
Tumor hypoxia is linked with loss of the p53 tumor sup-
pressor protein that may result in a loss of apoptotic ability
(Haensgen et al., 2001). Furthermore, hypoxia confers radio-
resistance because reactive oxygen radicals that are produced fol-
lowing radiation under well-oxygenated conditions contribute to
DNA damage (Rofstad et al., 2000). Hypoxia may also inhibit
the effects of chemotherapy via the same mechanism since in
the presence of oxygen drugs such as doxorubicin can produce
reactive oxygen species such as super-oxides that can damage
DNA (Luanpitpong et al., 2012). Hypoxia has also been shown
to down-regulate expression of DNA topoisomerase II, so that
drugs such as doxorubicin and etoposide that target this protein
will be inefficient (Ogiso et al., 2000).
Transient hypoxia can stimulate gene amplification, leading to
increased expression of genes that encode proteins that cause drug
resistance; these proteins include dihydrofolate reductase, with
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associated resistance to methotrexate and the multi-drug resistant
transporter P-glycoprotein (Wartenberg et al., 2003). Increased
expression of P-glycoprotein results in increased levels of sub-
strate drugs being pumped out of cells thus resulting in inadequate
intracellular levels to cause cytotoxicity (Matheny et al., 2001).
Factors influencing drug distribution within solid tumors
Anticancer drugs must reach target tumor cells through the vas-
culature. The penetration of drugs to tumor cells is reliant upon
convection and/or diffusion. Convection depends on pressure gra-
dients and given that the pressure within tumor blood vessels and
the tumor interstitium are both quite high, there is probably mini-
mal movement of drugs from the vasculature to the tumor via this
mechanism (Kuszyk et al., 2001). Diffusion involves the move-
ment of drugs along a concentration gradient, i.e., from areas
where they are concentrated (within the vasculature) to less con-
centrated regions (the tumor interstitium). Larger molecules tend
to move more slowly than smaller molecules via diffusion, and tis-
sue penetration will depend on consumption by the cells (Tredan
et al., 2007). Drugs that are water-soluble will diffuse more readily
through the extracellular fluid, although the diffusion coefficient
will depend on the nature of the ECM. Drugs with higher lipid sol-
ubility can penetrate into cells more easily (Undevia et al., 2005).
Drug half-life is also an important determinant influencing drug
penetration, since drugs with longer half-lives in the circulation
have a better opportunity to establish themselves within tumor
tissues (Undevia et al., 2005).
Quantifying drug distribution
Quantification of drug distribution is important in order to deter-
mine a drug’s ability to penetrate tissue within solid tumors. Both
in vitro and in vivo techniques have been used for quantifying drug
distribution. A common in vitro technique uses tumor spheroids,
and adherent tumor cells can grow spheroids to up to 3 mm in
diameter (Conger and Ziskin, 1983). Spheroids develop hypoxic
areas as well as central necrosis once they have reached ∼500µm
in diameter (Vinci et al., 2011). Drug distribution in spheroids can
be studied for fluorescent drugs, or by using autoradiography to
determine the distribution of labeled drugs (Lesser et al., 1995;
Kuh et al., 1999). An alternative is to generate multicellular layers
(MCL) on collagen-coated micro-porous membranes: the rate of
penetration can then be evaluated by adding a drug on one side
of the MCL and measuring its concentration on the other as a
function of time, as shown in Figure 1B (Wilson and Hay, 2011).
Spheroids and MCL have been used to study the distribution of a
wide range of drugs (Tannock et al., 2002), and most drugs show
rather poor distribution in tumor tissue.
Drug distribution can also be studied in tumors grown in ani-
mals. Growth of tumors in window and ear chambers allows
for direct observation of tumor microcirculation, but a disad-
vantage is that tumors are relatively small with limited areas of
hypoxia and/or necrosis (Hak et al., 2010). Tissue sections can
be obtained after drug treatment of animals bearing transplanted
tumors or human tumor xenografts and used for immunohis-
tochemical analysis. This analysis will allow the quantification
of fluorescent drugs in relation to blood vessels or regions of
hypoxia, and the technique can be applied to human biopsies
(Lankelma et al., 1999; Primeau et al., 2005; Fung et al., 2012).
These studies have revealed decreasing concentration of fluo-
rescent doxorubicin, mitoxantrone, or topotecan with increasing
distance from blood vessels (Hirst and Denekamp, 1979). Dis-
tribution of other drugs such as cetuximab, trastuzumab (Lee
and Tannock, 2010), and melphalan (Saggar et al., 2013) within
tumor sections can be quantified with the use of anti-IgG spe-
cific (for the former two) or melphalan DNA adduct specific
(for the former) monoclonal antibodies that recognize the drug
activity.
Most anticancer drugs are non-fluorescent so their distribu-
tion within tumor tissue is difficult to assess. An alternative is to
evaluate molecular markers of drug effect, using antibodies that
recognize cell proliferation (Ki67, cyclin D1, or bromodeoxyuri-
dine incorporation into DNA), antibodies that mark cell death or
apoptosis (e.g., caspase-3 or -6), and markers of DNA damage such
as γH2aX. We recently used antibodies to γH2aX, caspase-3 or -6,
and Ki67, and a computer-based algorithm, to quantify the distrib-
ution of (non-fluorescent) docetaxel (Saggar et al., 2013). Figure 2
depicts the expression of γH2aX following docetaxel treatment in
xenografts; use of this and the other markers show that docetaxel
also has limited distribution from tumor blood vessels.
Given the limited penetration of many chemotherapeutic
agents, cells that are distal from blood vessels do not receive
adequate amounts of drug to cause cell death. Thus, tumor cell
repopulation arising from areas where cells are not killed and
previously under-nourished (e.g., hypoxic regions) is probable,
and indeed we have recently shown that previously hypoxic cells
may reoxygenate and repopulate after treatment of human tumor
xenografts with doxorubicin or docetaxel (Saggar et al., 2013).
Tumor autophagy
Autophagy is a cellular process of self-consumption characterized
by sequestration of bulk cytoplasm, long-lived proteins, and cel-
lular organelles into double-membrane vesicles called autophago-
somes which are delivered to, and degraded in lysosomes (Lars-
son et al., 1985; Funderburk et al., 2010). The autophagoso-
mal membrane requires a kinase complex consisting of class
III phosphoinositol 3-kinase (PI3K), p150 myristylated protein
kinase and Beclin1 (Atg 6). Subsequently, two further protein
complexes are involved, the Atg4-Atg8 [also known as light
chain (LC3/MAP1LC3B)] and the Atg12-Atg5/Atg7-Atg16 com-
plex (Levine, 2007). Autophagy is thought to have at least three
roles within the cell (Lee and Tannock, 2006; Levine, 2007): (1) it
is a major pathway for quality control because it degrades damaged
or superfluous cellular components in order to avoid mutational
accumulation; (2) it may facilitate cell death as an alternative or
complementary pathway to apoptosis; (3) it provides an alternative
energy source by recycling cellular constituents during periods of
metabolic stress to maintain cellular viability. Such stressors may
include nutrient deprivation, hypoxia and cytotoxic agents, and
markers of autophagy co-localize with hypoxia in tumor sections
(Hoyer-Hansen and Jaattela, 2007). Hypoxic areas are reported to
be primary sites of autophagy in 12 head and neck tumor cell lines
(Rouschop et al., 2010) and recent data from our laboratory sug-
gest that tumors grown from cells that do not express Atg7 and
beclin-1 genes do not contain hypoxic regions.
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FIGURE 2 | Prostate cancer PC-3 xenografts (A) untreated control or
(B) treated with docetaxel (15mg/kg). (A,B) Show changes in γH2aX (in
cyan), a biomarker of drug effect, in relation to tumor blood vessels (in red)
at 10 min after injection. (C) Represents quantitative analysis of the
distribution of γH2aX-positive cells in relation to the nearest blood vessel
in tumors treated with docetaxel for 10 min (green line) and untreated
controls (blue line). Points indicate average of six mice per group; bars, SE.
♦: control; ◦: docetaxel.
Autophagy is prognostic of poor outcome in multiple tumor
types, including cancers of the breast, lung, and colon (Karpathiou
et al., 2011; Sivridis et al., 2011). High levels of autophagy have
been associated with resistance to systemic therapy in several
preclinical and clinical models presumably because it facilitates
survival of stressed or damaged cells through recycling of cel-
lular breakdown products (Yang et al., 2011). Hence targeting
of autophagy with pharmacological agents may be a mecha-
nism to improve the effectiveness of anticancer drugs for solid
tumors.
STRATEGIES TO IMPROVE THERAPY BY MODULATING THE TUMOR
MICROENVIRONMENT
Inhibiting tumor autophagy
The Atg proteins are involved in autophagosome formation –
a critical step required for autophagy to occur, therefore
the inhibition of autophagy can be achieved by knockdown
of Atg genes or by pharmacological inhibition. For exam-
ple, deletion of Atg7 and Beclin1 inhibited autophagy induced
by nutrient deprivation of cervical cancer cells and induced
cell death (Yu et al., 2004) while stable knockdown of Atg7
in human breast cancer cells inhibited cell growth in soft
agar and tumor formation in nude mice (Kim et al., 2011).
These strategies can also enhance tumor cell death induced
by diverse anticancer drugs in preclinical models (Yang et al.,
2011).
Agents which inhibit endosomal acidification, including
(hydroxy)chloroquine and proton pump inhibitors (PPIs), can
suppress autophagy and may therefore inhibit survival mecha-
nisms for nutrient deprived cells (Marino et al., 2010). Luciani
et al. (2004) reported the use of PPIs to sensitize cancer cells
and solid tumors to various chemotherapeutic agents. Multi-
ple mechanisms are probably involved, but appear to relate to
changes in acidity in both intra and extracellular compartments of
tumor cells. This group also reported that PPIs inhibit autophagy
(Marino et al., 2010) probably because fusion of autophagosomes
with acidic endosomes is central to the process, and we have
confirmed this. Several studies have shown that PPIs such as
omeprazole, esomeprazole, and pantoprazole have activity against
human hematopoietic and solid tumors; they may revert chemo-
resistance in drug-resistant tumors and directly induce killing of
tumor cells (Yeo et al., 2004; De Milito et al., 2007, 2010). Growing
evidence suggests that the major mechanism may be inhibition of
autophagy.
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Strategies to reduce interstitial fluid pressure
The interstitial fluid pressure (IFP) within solid tumors is often
high (Heldin et al., 2004; Lunt et al., 2008), and this can inhibit the
penetration of drugs into tumor tissue. This is particularly true
in human pancreatic tumors that are extremely resistant to sys-
temic cancer therapy (Olive et al., 2009; Provenzano et al., 2012).
Raised IFP is due, at least in part, to a dense ECM and high cell
density that lead to compression of blood vessels, and to inad-
equate lymphatic drainage (Ferretti et al., 2009). High IFP may
have an adverse effect on treatment since it may cause vascu-
lar compression and inadequate drug delivery. A recent study by
Provenzano et al. (2012) showed that there is an abundance of
hyaluronic acid (HA) in the ECM of pancreatic tumors. HA is a
large glycosaminoglycan that is associated with elevated IFP, and
treatment with a HA-targeting enzyme (PEGPH20) was able to
diminish HA levels and result in patent blood vessels and a corre-
sponding increase in doxorubicin penetration (Provenzano et al.,
2012). Other methods of improving vascular perfusion have also
been investigated: Olive et al. (2009) reported that reduction in lev-
els of tumor-associated stromal fibroblasts through disruption of
Hedgehog signaling resulted in increased angiogenesis and greater
penetration of gemcitabine into pancreatic tumors. The use of
HA-targeting enzymes (PEGPH20) and Hedgehog signaling dis-
ruptors (GDC-0449 and LDE225) are being investigated in clinical
trials.
Hypoxia-activated pro-drugs
Since hypoxic cells may survive after systemic drug treatment, and
since tumor hypoxia confers a particularly metastatic and aggres-
sive tumor phenotype, it is a logical target for new approaches to
therapy. Hypoxia-activated pro-drugs (HAPS) have been devel-
oped, such that a pro-drug is administered in an inactive form,
and is activated via a reduction reaction in hypoxic regions to
damage DNA (Wilson and Hay, 2011). Since the pro-drug does
not bind to DNA in oxygenated cells, it should diffuse readily
to hypoxic tumor regions. Several HAPs have been investigated
including tirapazamine, AQ4N, PR-104, and TH-302. Tirapaza-
mine was investigated in phase III clinical trials, but due to limited
clinical benefit (perhaps because of poor distribution in tumor tis-
sue of both the pro-drug, and the activated drug), further clinical
investigation was halted (Denny, 2010).
TH-302 is a 2-nitroimadazole whose nitro group under-
goes fragmentation releasing the active bromo-isophosphoramide
group that binds to DNA and causes cross-linkage to occur (Meng
et al., 2012). TH-302 has been shown to decrease the hypoxic
fraction and increase necrosis following treatment of many differ-
ent tumors in animals (Sun et al., 2012). In a randomized phase
II clinical trial of gemcitabine and TH-302 in pancreatic cancer,
combined therapy increased progression-free survival from 3.6 to
5.6 months (Borad et al., 2012) and a phase III trial is in progress.
Thus, TH-302 appears to be a promising addition to traditional
chemotherapy, and recent studies in our laboratory suggest that
it can inhibit the repopulation and reoxygenation of formerly
hypoxic cells following treatment of human tumor xenografts with
chemotherapy.
CONCLUSION
Limited drug delivery to tumors is an important cause of treatment
failure. The tumor microenvironment exerts effects that can alter
the delivery of agents to neoplastic cells. Novel therapies that are
able to leverage key characteristics of the tumor microenvironment
such as hypoxia-activated pro-drugs and PPIs have potentials to
result in improved therapeutic outcome.
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